glenmark pharma (ICICIsec) Few surprises due to IFRS, Growth intact

Impact on P&L and Balance sheet due to shift to IFRS; Recently Out-licenses GBR 500 to Sanofi Aventis
Date Rating Target Price Recommendation Price Broker house
17 May 2011 strong buy 396 306 ICICI securities Report

No comments:

Post a Comment